Alembic Pharma receives EIR from USFDA
New Delhi: Drug firm Alembic Pharmaceuticals said it has received Establishment Inspection Report from the US health regulator for its formulation facility located at Panelav in Gujarat.
"The company has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection carried out by them at our formulation facility at Panelav during the period from March 12-20, 2018," Alembic Pharmaceuticals said in a BSE filing.
USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.
Read Also: USFDA completes inspection at Alembic Pharma’s Panelav plant
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd